Abstract
Secondary Neoplasia (SN) after HCT belong to the most feared long-term complications. They include any malignant disorder occurring after HCT. There are three types of SN: therapy-related myeloid neoplasms, occurring mainly after auto-HCT; donor-derived malignancies after allo-HCT; and second solid neoplasms after either auto- or allo-HCT. Many of these SN have a higher incidence compared to the general population. In this chapter, pathophysiology issues, risk factors, screening and management recommendations are discussed. Since SN can occur even decades after HCT, life-long surveillance is needed.
You have full access to this open access chapter, Download chapter PDF
1 Definitions
Secondary neoplasia (SN) after HCT includes any malignant disorder occurring after HCT, irrespectively, if related or not to transplantation. For an individual patient, a clear relationship between HCT and SN often cannot be demonstrated. Posttransplant lymphoproliferative disorders are discussed elsewhere (see Chap. 45).
2 Types of Secondary Neoplasia After HCT
Therapy-related myeloid neoplasms (t-MN) (Pedersen-Bjergaard et al. 2000) | Donor-derived malignancy (DDM) (Sala-Torra et al. 2006; Wiseman 2011; Engel et al. 2019) | Second solid neoplasms (SSN) (Kolb et al. 1999; Rizzo et al. 2009) | |
---|---|---|---|
Definition | t-MDS or t-AML after exposition chemo- or radiation therapy | Hematologic neoplasms occurring in grafted donor cells | Solid cancers of any site and histology occurring after HCT |
Occurrence | Mainly after auto-HCT Not excluded after allo-HCT (Yamasaki et al. 2017) | After allo-HCT only | After allo-HCT and auto-HCT |
Appearance | Within the first 10 years mainly | Variable | Increasing incidental rate with longer follow-up |
Prognosis | Poor | Poor | Depends mainly on the cancer type |
3 Pathophysiology
3.1 Therapy-Related Myeloid Neoplasms
t-MN are mainly associated with cytotoxic chemotherapy and radiation therapy that the patient has received either before HCT or as conditioning. The causal role of ionizing radiation in the development of myeloid neoplasms has been demonstrated in atomic bomb survivors of Hiroshima/Nagasaki and in medical radiation workers employed before 1950.
Responsible cytotoxic drugs:
-
Alkylating agents, anthracyclines, and topoisomerase II inhibitors.
-
To a lesser extent antimetabolites and purine analogs.
-
Controversy exists on the role of azathioprine, methotrexate, hydroxyurea, and 6-mercaptopurines used for the treatment of malignant and nonmalignant diseases.
t-MN occur mainly after auto-HCT, where the healthy HCT has been exposed to cytotoxic effect (Diamond et al. 2023). Detecting clonal hematopoiesis mutations in cryopreserved cells before auto-HCT has been associated with a higher risk of t-MN (Gramegna et al. 2022). Rarely t-MN can be observed after allo-HCT. Persistent microchimerism with exposed residual recipient cells or autologous recovery may explain the development of t-MN after allo-HCT (Hoshino et al. 2022). After HCT for sickle cell disease, the 10-year incidence of leukemia and MDS is increased, mainly when conditioned with reduce-intensity and TBI-containing regiment. The onset of t-MN and graft failure after HCT are closely related (Eapen et al. 2023).
Today, increasingly cytotoxic drugs are applied after the allo-HCT, either as GVHD prophylaxis (posttransplant CY) or to prevent disease recurrence (posttransplant maintenance). Posttransplant CY does not seem to increase the risk of t-MN (Majzner et al. 2017; TCT). We do not yet know whether posttransplant maintenance therapy could increase the risk of t-MN after allo-HCT.
A germline cancer predisposition has been demonstrated in 15–20% of t-MNs, and acquired mutagenic effect of cytotoxic therapy with clonal hematopoiesis of indetermined potential (CHIP) is frequently the first step in the multihit development of t-MNs (Voso et al. 2021).
3.2 Donor-Derived Malignancy (DDM)
The pathogenesis of donor-derived hematological malignancies is not fully understood but is likely multifactorial (Sala-Torra et al. 2006; Wiseman 2011; Williams et al. 2021; Gibson et al. 2022):
-
Treatment damage to bone marrow microenvironment from previous chemotherapy, radiation, and treatments to prevent GVHD
-
Transplantation of a malignant clone, or germline or somatic mutations from the donor
-
Stress of rapid clonal expansion after transplant
Reported donor cell leukemia are AML, MDS, ALL, CML, and lymphoid neoplasms including CLL (Engel et al. 2019). The risk of DDM in allogeneic hematopoietic cell transplantation is driven by somatic myelodysplastic syndrome-associated mutations or germline predisposition in donors (Gibson et al. 2022).
Clonal hematopoiesis can be transmitted from a donor to a recipient during allo-HCT. Exclusion of candidate donors with clonal hematopoiesis is controversial since its impact on recipient outcomes and graft alloimmune function is uncertain.
Over 20% of donor-derived myeloid neoplasms carry chromosome 7 abnormalities. Gene sequencing of the donor cells allowed to detect a number of candidate genes that could contribute to the development of DDM (Williams et al. 2021). Malignant clones transferred to the recipient can be of lymphoid origin, observed in older donors, and may evolve into a lymphoid neoplasm in the immunosuppressed host.
3.3 Second Solid Neoplasms (SSN)
Little is known about pathogenesis of SSN after HCT. An interaction between cytotoxic treatment, genetic predisposition, environmental factors, viral infections, GVHD, and its immunosuppression may play a role.
Three main types of SSN (Rizzo et al. 2009):
-
Radiation-related SSN
-
Proven for thyroid, breast, and brain cancers
-
Occur after a long latency (≥10 years after radiation)
-
Is dose related
-
-
GVHD/immunosuppression-related SSN
-
Squamous cell carcinoma of the skin and oropharyngeal area
-
Short latency
-
Can occur at different localizations
-
-
Association with viral infection
-
HCV infection associated with hepatocellular cancer
-
HPV-related precancer or second cancer, with increased cumulative incidence for cervical, head and neck, vulvar, vaginal, anal, and penile second cancer (Zhao et al. 2021)
-
4 Frequency and Risk Factors (See Table 47.1)
4.1 Remarks on SSN
The CI of second solid cancer is 2.2% at 10 years and 6.7% at 15 years (Rizzo et al. 2009).
Increased risk for SSN after HCT has been demonstrated from breast, thyroid, skin, liver, lung, oral cavity and pharynx, brain and CNS, bone and connective tissue cancers and malignant melanoma.
An individual patient can present several subsequent different SSN after HCT. Up to five different solid cancers have been observed in a patient treated with allo-HCT.
Digestive system and particularly colorectal cancers have not been proven to be increased after HCT (Heydari et al. 2020). In non-transplanted cancer patients, second colorectal cancers are increased when treated with abdominal radiation (Henderson et al. 2012; Rapiti et al. 2008; van Eggermond et al. 2017).
So far there are few long-term data on SSN after RIC. A single-center study shows an increased rate of SSC compared to MAC during the first 10 years post-HCT (Shimoni et al. 2013). The 10-year cumulative incidence of SSC following RIC reached 12.9%, with an overall SIR of 1.03–1.9, mainly significant for head and neck and bladder cancers. Second malignancy seems to be higher than expected in treated allo-HCT recipients conditioned with RIC but still longer follow-up time with larger cohorts is needed for definitive assessment (Del Galy et al. 2022).
The outcome of SSC is mainly dependent on the type of second cancer. Standardized mortality ratio was higher, compared with de novo solid cancers, for melanoma, prostate, breast, kidney, bladder, colorectal, and endometrial cancers but not for the other cancers (Tichelli et al. 2019). Most subsequent solid cancers occurred at younger ages than primary cancers, emphasizing the need for cancer screening at younger ages (Inamoto et al. 2018).
5 Screening (Majhail et al. 2012; Inamoto et al. 2015) (See Also Chap. 21)
5.1 Therapy-Related Myeloid Neoplasms
Annual monitoring of full peripheral blood counts during the first 10 years after auto-HCT (most t-MN occur within 10 years after HCT).
If unexpected abnormalities in the blood count are observed (increased MCV, cytopenia, dysplasia in peripheral blood, thrombocytosis, leukocytosis, monocytosis), extended analysis of blood and bone marrow is warranted, including cytogenetics and NGS (Bachiashvili et al. 2022).
5.2 Donor-Derived Malignancy
Chimerism monitoring of the malignant cells is needed in case of “relapse” or new hematological malignancy after allo-HCT.
Whether to search for clonal hematopoiesis, lymphoid malignant clone, and germline mutations in the donor in case of DDM remains controversial.
5.3 Second Solid Cancer (Socie and Rizzo 2012; Inamoto et al. 2015)
Lifelong screening for SSN is recommended after auto-HCT and allo-HCT.
General recommendations are as follows:
-
During annual control, clinical screening and reviewing for possible symptoms of SSN.
-
Follow country-specific or international guidelines for cancer screening recommendations for the general population.
-
Be informed and counselled about the risk of SSN.
Specific recommendations are included in Table 47.2.
6 Treatment
Neoplasm | Treatment |
---|---|
t-MN | Same treatment than de novo myeloid neoplasms Early donor search and rapid allo-HCT (Finke et al. 2016; Kroger et al. 2011; Metafuni et al. 2018) Decision-making including consideration of cumulative toxicity due to previous HCT, age, and comorbidity |
DDM | No standard treatment Treatment depends on the nature of disease Reported treatments (Engel et al. 2019) • Retransplantation • Conventional chemotherapy • DLI • Palliation |
SSN | Should be treated as de novo cancers of the same type |
7 Outcome
Neoplasm | Outcome |
---|---|
t-MN | Generally very poor Median survival of 6 m Identical outcome than t-MN in general |
DDM | Few data available In most cases, mortality high and OS poor In a small series of 47 DDM, median survival 32.8% months Death mainly due to progression or relapse of DDM |
SSN | Mainly dependent on the type of SSN (Ehrhardt et al. 2016; Tichelli et al. 2019; Inamoto et al. 2018) Favorable outcome • Thyroid, breast, prostate, melanoma, cervix Intermediate outcome • Oropharyngeal, colorectal, bladder, renal, ovarian, endometrial Poor outcome • Pancreas, lung, brain, hepatobiliary, esophageal |
Key Points
-
Three types of secondary neoplasia may occur after HCT: therapy-related myeloid neoplasms (t-MN), mainly after auto-HCT; donor-derived malignancy (DDM) after allo-HCT; and second solid neoplasia (SSN) after auto-HCT and allo-HCT.
-
Pretreatment or conditioning with radiation and/or chemotherapy including alkylating agents, anthracyclines, and topoisomerase II inhibitors is mainly responsible for t-MN.
-
DDM are extremely rare and are either transmitted from the donor or newly transformed in the host.
-
Non-squamous second solid cancers (breast, thyroid, brain, etc.) are strongly related to local radiation or TBI and occur with long delay after HCT. Squamous cell carcinoma of the skin, the oral cavity, and the pharynx is related with chronic GVHD and can occur early after HCT. Conditioning with RIC does not seem to reduce the risk of second cancer.
-
Outcome of t-MN is poor, and allogeneic HCT represents the only curative treatment.
-
Outcome of SSN depends mainly on the type of second cancer; second solid cancer should be treated as a de novo cancer of the same type.
References
Bachiashvili K, Francisco L, Chen Y, et al. Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma. Cancer. 2022;128(7):1392–401.
Cohen PA, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT late effects working party study. J Clin Oncol. 2007;25:2449–54.
Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105:3802–11.
de Latour RP, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618–24.
Del Galy AS, Rousseau A, Capes A, et al. Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplant. 2022;57:1365–72.
Diamond B, Ziccheddu B, Maclachlan K, et al. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023;141:2359–71.
Eapen M, Brazauskas R, Williams DA, et al. Secondary neoplasms after hematopoietic cell transplant for sickle cell disease. J Clin Oncol. 2023;41:2227–37.
Ehrhardt MJ, Brazauskas R, He W, et al. Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:83–8.
Engel N, Rovo A, Badoglio M, et al. European experience and risk factor analysis of donor cell derived leukaemias following haematopoietic cell transplantation. Leukemia. 2019;33:508–17.
Finke J, Schmoor C, Bertz H, et al. Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51:771–7.
Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-late effect working party. Blood. 2008;111:939–44.
Gibson CJ, Kim HT, Zhao L, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022;40(2):189–201.
Gramegna D, Bertoli D, Cattaneo C, et al. The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. Ann Hematol. 2022;101(6):1227–37.
Henderson TO, Oeffinger KC, Whitton J, et al. Summaries for patients. Increased risk for gastrointestinal cancer in childhood cancer survivors. Ann Intern Med. 2012;156:1–36.
Heydari K, Shamshirian A, Lotfi-Foroushani P, et al. The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta analysis. Clin Transl Oncol. 2020;22:1825–37.
Hoshino T, Hatsumi N, Iino H, Takada S. Therapy-related myeloid neoplasms of recipient origin after allogeneic hematopoietic stem cell transplantation for acute leukemia. Int J Hematol. 2022;116(6):902–10.
Inamoto Y, Shah NN, Savani BN, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50:1013–23.
Inamoto Y, Matsuda T, Tabuchi K, et al.; Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group. Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation. Blood Adv. 2018;2:1901–1913.
Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late effects working party of the European cooperative group for blood and marrow transplantation and the European late effect project group. Ann Intern Med. 1999;131:738–44.
Kroger N, Zabelina T, van Biezen A, et al. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 2011;96:291–7.
Leisenring W, Friedman DL, Flowers ME, et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006;24:1119–26.
Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117:316–22.
Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47:337–41.
Majzner RG, Mogri H, Varadhan R, et al. Post-transplantation cyclophosphamide after bone marrow transplantation is not associated with an increased risk of donor-derived malignancy. Biol Blood Marrow Transplant. 2017;23:612–7.
Metafuni E, Chiusolo P, Laurenti L, et al. Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: monocentric observational study and review of the literature. Mediterr J Hematol Infect Dis. 2018;10:e2018005.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95:3273–9.
Rapiti E, Fioretta G, Verkooijen HM, et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int J Cancer. 2008;123:1141–5.
Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1175–83.
Rosenberg AS, Brunson A, Tuscano J, et al. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J. 2021;11:5.
Sala-Torra O, Hanna C, Loken MR, et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:511–7.
Shimoni A, Shem-Tov N, Chetrit A, et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced. Leukemia. 2013;27:829–35.
Socie G, Rizzo JD. Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol. 2012;49:4–9.
Song JS, London WB, Hawryluk EB, et al. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52:989–97.
Tichelli A, Beohou E, Labopin M, et al. Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients. JAMA Oncol. 2019;5:229–35.
van Eggermond AM, Schaapveld M, Janus CP, et al. Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. Br J Cancer. 2017;117:306–14.
Voso MT, Falconi G, Fabiani E. What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasm. Blood. 2021;138:749–57.
Williams L, Doucette K, Karp JE, Lai C. Bone Marrow Transplant. 2021;56:1335–49.
Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011;17:771–89.
Yamasaki S, Suzuki R, Hatano K, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. Bone Marrow Transplant. 2017;52:969–76.
Zhao H, Duan Z, Li M, et al. Transplant Cell Ther. 2021;27:1016.e1–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2024 The Author(s)
About this chapter
Cite this chapter
Tichelli, A., Rovó, A. (2024). Secondary Neoplasia (Other Than PTLPS). In: Sureda, A., Corbacioglu, S., Greco, R., Kröger, N., Carreras, E. (eds) The EBMT Handbook. Springer, Cham. https://doi.org/10.1007/978-3-031-44080-9_47
Download citation
DOI: https://doi.org/10.1007/978-3-031-44080-9_47
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-44079-3
Online ISBN: 978-3-031-44080-9
eBook Packages: MedicineMedicine (R0)